Compare DexCom, Inc. (DXCM) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Royal Caribbean Cruises Ltd — how do they compare? DexCom, Inc. trades at $77.36 (market cap $28.06B), while Royal Caribbean Cruises Ltd trades at $289.15 (market cap $78.36B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 2.8× DexCom, Inc.'s market cap, and Royal Caribbean Cruises Ltd pays a 1.71% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | RCL | |
|---|---|---|
Market Cap | $28.06B | $78.36B |
Sector | Health | Consumer Cyclical |
52-Week High | $89.53 | $365.84 |
52-Week Low | $54.84 | $246.71 |
Enterprise Value | $27.03B | $99.64B |
Dividend Yield | — | 1.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
Royal Caribbean (RCL) trades at $289.26, up 2.18% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $328. The company demonstrates strong fundamentals with revenue growth from $16.5B in 2024 to $17.93B in 2025, net income margin of 24.36%, and robust cash flow from operations of $6.47B. Recent news highlights Caribbean demand offsetting European weakness and upcoming Q2 2026 earnings.
RCL presents a favorable investment case with solid profitability, earnings beats, and analyst optimism, though risks include high debt levels, economic sensitivity, and competitive pressures. The stock's current valuation below consensus target suggests potential upside, contingent on sustained travel demand and execution of growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
